Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

• Status: Not yet recruiting
• Trial end date: 2025-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis
• Collaborators: Doris Duke Charitable Foundation; National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Alendronate

Criteria

Inclusion Criteria:

• Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)

• Ability to provide written informed consent

• Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner

• Negative urine pregnancy test for anyone of childbearing potential at study entry

Exclusion Criteria:

• Pregnant women

• Adults unable to consent

• Individuals who are not yet adults (infants, children, teenagers)

• Prisoners

• Hospitalizations (for any cause) within 2 weeks of study entry